Skip to main content
. 2020 May 5;110(1):136–145. doi: 10.1007/s00392-020-01661-6

Fig. 2.

Fig. 2

Schematic illustration of myocardial transit-time (MyoTT) depicting the different transit-time ‘through’ the myocardial microvasculature between cardiac amyloidosis (CA) patients (first row), hypertrophic cardiomyopathy (HCM) patients (second row), and healthy controls (third row)